News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

USPTO Issues Patent for CardioGenics Holdings Inc.' Signal Amplification Technology


6/29/2011 7:51:21 AM

MISSISSAUGA, Ontario, June 29, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (CGNH.OB) announced today that the United States Patent & Trademark Office (USPTO) has notified the company that its patent application has been granted (issued patent # 7,964,415).This patent coversCardioGenics Inc.'s proprietary signal amplification technology, which is a key component of the core technology for CardioGenics' Ultra-Sensitive QL Care Analyzer. CardioGenics' unique methodology for signal amplification enables a decrease in the amount of binding reagents used in immunoassay diagnostic tests, such as those to be performed on the QL Care Analyzer, which, in turn, results in improved signal-to-noise ratio thereby increasing testing sensitivity.

"We are very pleased that the USPTO has recognized the unique nature of CardioGenics' signal amplification technology," said Dr. Yahia Gawad, CEO of CardioGenics. "This patent is an important addition to our patent portfolio since it addresses a key component of the technology that permits the ultra-sensitive performance of our QL Care Analyzer," continued Dr. Gawad.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's proprietary microspheres technology and SAVAsphere magnetic beads are developed and marketed through the Company's Luxspheres subsidiary. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com and www.luxspheres.com.

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.

SOURCE CardioGenics Holdings Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES